Hi, and good afternoon. On behalf of HC Andersen Capital, I would like to welcome you all to this presentation of the Q3 2026 report from SP Group that was published yesterday. My name is Rasmus Køjborg, and I have the pleasure of welcoming CEO Lars Bering and CFO Allan Jeppesen. They promised to take us through the numbers and the recent highlights, so a warm welcome to you. Before I hand over, also a warm welcome to those of you who signed up for today's presentation. As usual, you can ask your questions in the chat room. If you are not comfortable writing in English, you can write them in Danish, and I will do the translation. Please do not hesitate to ask any questions to the management here of SP Group.
Should you wish to see the presentation again, it will be published afterwards on different platforms. With that, I will turn off my camera and then revert again for the Q&A. For now, I will leave it to you, Lars and Allan.
Thank you.
Thank you very much, Rasmus, and welcome to our presentation of the result for the third quarter 2026. My name is Lars Bering. I am CEO of SP Group.
My name is Allan Jeppesen, CFO of SP Group.
Together with Søren Ulstrup, we make up the executive board. Today, we will start with a short introduction to SP Group for those of you who are listening in for the first time. After that, go through the third quarter and the first nine months of 2026, in which we have set several records. Allan and I will share the presentation during today and complement each other along the way. SP Group makes technical plastic solutions. This can be products for the healthcare sector or components that sit inside our customers' products for many years. 77% of our revenue comes from our sub-supplier business, and 23% comes from our own products. This is plastic products sold in their own brands around the world. We have just over 3,000 employees at 35 factories in a global footprint.
18% of the raw material that we are using in our production is recycled materials, and we have a target to reach 25% in 2030.
Well, healthcare is our largest product group with 35% of the revenue, followed by clean tech with 29%, food tech with 14%, and the category other with 22%. All four groups have grown in 2026, and we will come back to that later in this presentation.
Yes. SP Group is organized in a number of independent units, each owning their technology and their customers. The light green units on the left-hand side on this slide are the ones with their own products, including Ergomat, SP Medical, and MedicoPack. On the right-hand side are the sub-supplier units, from injection molding at SP Moulding to composites and polyurethanes at SP Tinby. There is also a new name on the page since August. OGM now sits alongside SP Moulding under injection molding. The model is decentralized on purpose because we want decisions to be made close to the customers to ensure a high level of agility and efficiency. The group's task is to get the units to help each other with purchasing, knowledge sharing, and cross-selling. Idé-Pro and OGM are two very good examples of that this year.
Allan, will you show us where we are in the world?
Yes. We are today present in 13 countries around the world and manufacture in 10 of them. The U.K. is the newest, and it was added with the acquisition of OGM back in August. The map on the screen shows the breakdown of sales of 2025. This year, in 2026, the picture is the same. 71% of the revenue in the first nine months was generated outside Denmark. Growth in 2026 has been geographically broad. Sales outside Denmark rose by 35%, and sales to Danish customers rose by 39%. In other words, we are not dependent on any single markets. Looking at the workforce, almost seven out of 10 employees now work outside of Denmark.
We come to the highlights, and let me start with the most important. After nine months, we have earned more than we did in the whole of last year. Profit before tax is DKK 350 million against DKK 345 million for the whole of last year. The third quarter was the best quarter in the company's history. Revenue rose 43% to DKK 938 million, and the organic growth was 23.9%. However, the growth should be seen in the light of the dynamic we saw in the second half of last year, where several orders were moved from third quarter to fourth quarter. We are also earning more on the revenue now. Profit before tax rose 58%, and the EBT margin was 10.9% against 9.9% in third quarter last year. In August, we told you about what we are working on.
Today, we can tell you that much of this is up and running. OGM is part of the group. We have spent a lot of time introducing the organization to each other, especially the sales team, and there is already a very good collaboration between the companies. Idé-Pro is delivering cross-selling, new projects to existing SP Group customers, and in Poland, SP Meditec has taken 1,700 sq m of new controlled production environment into use. Also some news. With the help of Idé-Pro, Ergomat has established a local production and distribution in India, and we have already shipped the first orders. Finally, we have expanded the share buyback program with DKK 40 million and expanded it to the end of April next year. Coming to our own products, we have seen a good growth. Sales rose by 20.3% to DKK 677 million.
This is the highest level we have achieved after three quarters. The progress comes from TPI's ventilation products and ergonomic products from Ergomat. Sales of the pharmaceutical packaging from MedicoPack and our guidewires from SP Medical are flat, as we also told you about in August. Two things to bear in mind. Own products are often sold in larger projects, so individual quarters can fluctuate. Ergomat's new production in India is set to bring us closer to customers in Asia, and here we expect growth in the future. Sub-supplier revenue account for the largest part of our growth. We sold for DKK 2 billion and DKK 211 million in the first nine months. This is DKK 652 million or 41.8% more than last year. Part of the growth come from acquisitions. Idé-Pro is included in the full period and OGM from August 19. The acquisitions are not the whole explanation.
Group organic growth was 21%, and a large part comes from sub-supplier revenue. The companies we already have has also performed strongly in the period. However, what I'm most pleased about is that we are still winning new work with both existing and new customers. The activity level in the factories are high, which are high. Then it's the product groups.
Yes. All four of our product groups have grown in the first nine months of 2026. As Lars just mentioned during the highlights, the total revenue has grown by 36%. When we look at the developments in the four group, healthcare has picked up speed. The product group healthcare grew by 18% in the first half of 2026 and by 31% in the third quarter. Year-to-date growth in this category has been 22% in total. Revenue in healthcare is DKK 1 billion and DKK 25 million in the first nine months. Clean tech is holding its level with 40% growth both in the quarter and in the first half of 2026. The food tech category has grown by 48% year to date. In the third quarter, growth was 28%, so the pace in this category is slightly lower than in the spring.
The category other has grown by 51% year to date to a revenue of DKK 623 million. Growth has been high throughout the year and is partly driven by the acquisition of Idé-Pro and OGM.
Thank you, Allan. In August, we explained why we acquired OGM. Today, I would like to tell you how things have gone in the first three months. What we have seen has been confirmed. OGM is a well-run company founded in 1962 with 190 employees at two factories. We have used the time to get the sales teams to know each other and started the integration. The customer overlap between OGM and the rest of SP Group is limited, so the opportunities for cross-selling are very good. The first projects have already been started. OGM has also become a customer of Idé-Pro, which is working on the first tool for OGM. The rationale is the same as in August. This is a new bridgehead for SP Group into the U.K.. It is more advanced products.
It is box build as a competence and access to a global production platform for OGM's customers.
Well, Lars has given you the headlines. I will take you through a bit more of the figures behind them. Revenue in the third quarter rose by 43.2% to DKK 938 million. 23.9% of this was organic, and 19.3% came from the acquisition of Idé-Pro and OGM. EBITDA rose by 42.1% to DKK 179 million. The EBITDA margin was 19.1% against 19.3% last year. Please note that in Q3 2026, we expensed DKK 5 million in connection with the acquisition of OGM. The EBT margin was 10.9%, 1 percentage point higher than in the same period last year. When we look at the year-to-date figures in September, revenue was DKK 2 billion 888 million. That is 36.1% more than last year, and only DKK 60 million short of the total revenue of the whole 2025. More than half of the growth is organic, 21%, and the acquisition contributed with 15.1%.
EBITDA rose by 38% to DKK 567 million, and the EBITDA margin year-to-date is 19.9% against 19.7% last year. EBIT rose by 47.7% to DKK 398 million, and profit before tax rose by 52.6% to DKK 350 million. All three margins are higher than last year, and the EBT margin for the period year-to-date is 12.1% against 10.8% last year, which actually puts this in the middle of the guidance range for this year. When we look at the cash flows from the operating activities in the first nine months, we see that we have generated DKK 410 million, DKK 83 million more than last year. This was achieved through growth, which actually has required DKK 55 million more in working capital. Earnings per share rose by 58% to DKK 23.42. That is more than for the whole 2025, which was DKK 22.13.
Net interest-bearing debt at the end of September was DKK 1,497 million, an increase of DKK 37 million since the turn of the year. The main reason for the increase is the acquisition of OGM and the debt taken on in that connection. The gearing measured as net interest-bearing debt divided by EBITDA is two times against 2.4 at the turn of the year, and we expect it to be below 2.0 at the end of this year. Equity end of September was DKK 1,962 million, and the equity ratio at the end of September was 44%. Lars, would you go through the long-term development?
Yes, because a single quarter does not tell the whole story about SP Group. That is why we always show the long-term trend in our presentations. Over the past 12 months, our revenue has been DKK 3.7 billion. 10 years ago, back in 2016, it was DKK 1.5 billion. That is almost two and a half times as much in 10 years, and an average growth rate of 9.6%. Growth has come in two ways, organically and through more than 20 acquisitions. Idé-Pro and OGM are the most recent, and they are both included in the last bar. Our ambition for 2030 is a level of DKK 4.5 billion, and we are very well on the way to that ambition. We have not only grown larger, we are also earning more on our revenue. EBITDA is DKK 754 million over the past 12 months.
The margin has risen from 13% in 2016 to 20.3% in the past 12 months. The four drivers for this increase are the same as always, and they are still working. I will give you a current example of each. Own products, Ergomat, are now producing in India, where we have started to distribute in Asia. In Eastern Europe, new Meditec production space has been taken into use in Poland. Automation, we are working with this in all our factories, with robots in production, AGVs for internal transportation, and most recently, we have implemented AI agents to handle administrative work. The value chain. With OGM, we can build finished products with electronics, including testing and packaging. The same trend applies to EBT, which is affected by the same drivers.
EBT is almost four times up in the past 10 years, from DKK 123 million in 2016 to DKK 466 million in the past 12 months. The margin is 12.5% against 8% in 2016. Finally, we are very pleased that we have earned DKK 350 million in the first nine months. That is more than the whole of 2025.
Let's look at the outlook for 2026. This year, we have upgraded our revenue guidance twice, most recently back in August with the acquisition of OGM. Yesterday, we narrowed our guidance by raising the bottom of this range. We now expect a revenue growth of 26%-30%, compared with the 24%-30% previously. That corresponds to a revenue in the level of DKK 3.7 billion-DKK 3.8 billion. Acquisitions are expected to account for 16- 17 percentage point of this growth. If we look at the quarterly development shown at the right of this slide, revenue in the second and the third quarter of 2025 was lower, partly because of the tariff challenges caused projects to be postponed to the fourth quarter.
This means that in the fourth quarter of 2026, we will be measured against the last year's largest quarter, where part of the revenue came from projects moved from the previous quarters. In 2026, revenue has been more evenly high in all three quarters, driven by both organic growth and the acquisition of Idé-Pro and OGM. We continue to expect an EBITDA margin at a level of 19%-21% and EBT margin of 11%-13%.
Thank you, Allan. If there are three things to remember from today, they are these. First, this has been the best third quarter ever. The EBT margin has improved despite the acquisition of OGM and a lower share of own products. Second, the growth that we have realized is broad-based. It comes from all our four product groups, and it comes both from our own products and from our sub-supplier business. There has been a good organic growth as well. Third, what we have set in motion is up and running. OGM is a part of SP Group. Idé-Pro is delivering cross-selling. The production in Poland has been taken into use, and Ergomat is producing in India. As Allan said, we have narrowed the outlook for the year by raising the bottom of the range, and we have expanded the share buyback program yesterday. Thank you for listening.
We are now ready to take your questions.
Thank you very much, Lars and Allan. Yes, let's do some of the questions. As we had it earlier today, there's one regarding your outlook and the implied growth here in Q4. As it says here, implied revenue growth in Q4 is 0%-14%, with acquisitions contributing 16-17 percentage points for the full year. That implies negative organic growth in Q4. Is that purely the comparison base from the project postponement in 2025, or do you see a real slowdown in Q4?
This is the first what you mentioned, as what we are seeing. We still see a very high activity level in the factories and a good order book. It is the first part. It is hard to measure up to a quarter like the one we had in last year, quarter four last year.
Thank you. Then another question we also had earlier today, that's for your long-term ambitions. When are you updating your 2030 targets? They look to be realized in 2027 or 2028, definitely not in 2030.
There is a very, very good possibility that we can be above DKK 4.5 billion in 2030. You are completely right about that. If we are able to do that before 2030, then we will, of course, come back to the ambitions and update them. I think what is important to look at is also what we have said, is that we want to achieve a growth rate of 6%-9% in the years, and we can do, and hopefully be able to do more if we could do large acquisitions. That is what we are aiming to do.
Thank you. Then another question here on your U.S. facilities. Let me just I think we have those in the appendix here as well, if I am not wrong. It should be here, because there is a question related to this. Let me just see here. How is the U.S. production facility progressing, and what is the capacity utilization currently?
The U.S. plant is progressing really well. Revenue has come up as expected, and we are still busy to implement a lot of new tasks in the factory. The factory is not full yet, but the plans we have for the coming years for that factory will make them full.
Good. Then another question related to your acquisition. As we can see from this one, you made some 15 plus acquisitions since 2015, then moving to your global footprint, this slide here, because the question goes like this. You made more than 15 acquisitions since 2015. Which capability or geography is still missing from the group that you would like to add? We heard that you have been doing some expansion in India, but are there other areas that you would like to expand to?
You can see on the map here that we have most our revenue in Europe. We would, of course, like to grow both in the U.S. and in Asia as well, because our customers are seeking good suppliers with a strong regional production platform. When it comes to capabilities, there are still niche areas where we would like to expand, but it is in the smaller area.
Good. One of the examples of the capabilities you are expanding to is the OGM acquisition here, because there was a question related to this also. Let me just see. Just a second. The U.K. is a completely new production market for you. How different is this to operate there post-Brexit in terms of customs, certification, and labor costs?
Overall, we have learned that the business, the OGM business in Oxford, is a business that in many ways, culturally-wise, are very similar to us. They run a production with some very advanced products to their customers, which they have been developing skills for over the years. What we would like to do is to bring these box build competencies into our other factories, both in Europe, but also in Asia and in the U.S.. For us, the potential is that the OGM's customers can have production in either East Europe or in the U.S. or in India with a very simple setup and still controlled by OGM. That is where we believe the real benefit is. We have no plans of having, right now, huge shipments across the borders.
What we see is that more and more our customers prefer that the components that they need are produced very close to where they actually need them.
Yes, then a follow-up on this box build, which is a new capability for the group, and you mentioning it, that you will roll it out in other factories. Is there any timeline for this, or do you still need to I think you only owned OGM for about three months, so you still need some time to learn more about this capability.
We are in progress of planning that part. Yeah.
Good. Then there is a few question related to your I think we have it here on the highlights, related to your margins here in Q3. Could you elaborate on the margin development in Q3, gross margin, EBITDA, EBIT margins decline compared to the first half of 2026? What were the main drivers for this development?
Well, we have still performed on the EBT margin level as last year, actually a bit better, as mentioned. But when we look at Q3 and compared to the two previous quarters, we see a lower share of own products, which often gives a smaller margin. So the share of own products have had an impact on Q3.
Good. A follow-up on this. How much of the organic growth in Q3 came from price, and how much is related to volume?
It is by far mostly related to volume.
Good. Another question to your global footprint here, because there is a question here that goes, you now operate 33 factories across nine countries. At what point does that footprint become a cost and complexity issue, and are there sites you would consider consolidating?
We are always looking at consolidating opportunities. However, it is also important to have in mind that what we do at these 35 factories around the world is very different in many of them. We are also doing small niche operations with highly specialized people, therefore, it would not make sense to just put it all together in one big factory, because we do not believe that would actually increase our margin. Our decentralized structure with a strong local management team actually enable us to make fast and good decisions close to the customers, also make an efficient factory setup.
Good. Thank you. Then a question to your own products here. Own products carry higher margins than subcontracting work. If the mix keeps shifting towards subcontracting, where does the group EBIT margin settle over time?
It, of course, depends on how things develops. We have no plans that we should have a low share of own products. We would like to have our own products to grow faster than the average growth. However, we have been able to acquire two fantastic companies with Idé-Pro and OGM, which we believe can develop SP Group in a very positive direction. We will continue to develop new own products, and we are, of course, also looking for acquisitions with own products to expand that part of the business.
Good. Then a question related to your products group here, as we also had in the Danish presentation earlier on. If we look at the other part, it is around 22% now. It grew around 50% on a nine-month basis. Actually, I think if we look at it on a Q3 basis alone, it was almost 100% at 97.8%. What exactly sits behind this, and how large is the defense exposure today?
Well, of course, the acquisition of OGM and Idé-Pro has an impact on this product category. When looking into the details of the category other, we do not see defense being significantly higher than the previous years.
Good. Then I think we are at the last question here. If we look at your net interest-bearing debt, it is around DKK 1.5 billion or two times EBITDA, and you have covenants around 3.5, if I am not wrong. How much room is there really for sort of the next acquisition, and is the pipeline still active, or are you focusing most of your time on Idé-Pro and OGM at the moment?
We are doing both. We are focusing on integrating Idé-Pro and OGM, and then we are, of course, also looking at the pipeline for looking for new possibilities for the future. We believe that the debt level that we have now is a comfortable area, but we also see possibilities for further acquisitions.
Good. Thank you. That was the last question. Thank you very much, Lars and Allan, for joining us here today.
Thank you. Thank you to all of you who has been listening in.
Yes, also from me, thank you very much, and thank you for the questions here. I just wish you a nice day and evening. Thank you.
Thank you.